-- Announced full data from ROSE2 Phase 2 clinical trial evaluating combination of obicetrapib and ezetimibe, which met the primary endpoint with 63.4% median reduction in LDL-C (p
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
Watch NewAmsterdam Pharma's latest callNewamsterdam Pharma (NASDAQ:NAMS) Q2 2026 Earnings Call · Replay · Aug 5Read the transcript of Newamsterdam Pharma (NASDAQ:NAMS) Q2 2026 Earnings CallNewAmsterdam Pharma Company N.V. on 6ix
Story so far
Earlier from NewAmsterdam Pharma
- NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease
- NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares
- NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares
- NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares
- NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients
Later from NewAmsterdam Pharma
- NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
- NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
- NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation
- NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer
- NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
Follow NewAmsterdam Pharma into a list and get an email when it puts out news.
Follow NewAmsterdam Pharma